Given the heterogeneity of breast cancer, future studies should evaluate NAR's effects on triple‐negative (MDA‐MB‐231) and HER2‐positive (SK‐BR‐3) cell lines to determine whether its cytotoxic effects are hormone receptor‐dependent. Here, ERBB2 is linked to breast carcinoma.